DLG Naturals, Inc.

CLOSEOUT LETTER DLG Naturals, Inc. MARCS-CMS 622277 — July 20, 2023 More Warning Letters Warning Letters About Warning and Close-Out Letters Product: Dietary Supplements Recipient: Recipient Name Mary Jo Knueppel Recipient Title Chief Executive Officer DLG Naturals, Inc. 2949 Venture Drive Suite 100 Janesville , WI 53546-8502 United States Issuing Office: Office of Human and Animal Food Operations – West Division 1 United States Dear Ms. Knueppel: The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter CMS 622277 dated April 28, 2022. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ Boun M. Xiong Compliance Officer, West Division 1 - CB Office of Human and Animal Foods Operations Content current as of: 07/21/2023 Regulated Product(s) Dietary Supplements